Topic resource collection
Approved comparison material connected to this topic.
5 resourcesRead both sides
BPC-157 FAK-paxillin pathway activation, VEGF/bFGF upregulation, MMP-9 inhibition Preclinical models show 38–43% improvement in tendon healing and cartilage preservation; no Phase 3 human trials 200–500 mcg daily subcutaneous inj…
BPC-157 VEGF upregulation, angiogenesis, fibroblast recruitment 250–500 mcg/day Subcutaneous or IM near injury site Preclinical animal studies; no Phase 3 human trials Most robust preclinical data for acute soft tissue injury; la…
BPC-157 VEGF upregulation → angiogenesis at injury sites; promotes fibroblast migration and collagen synthesis Subcutaneous injection (daily) 200–500mcg/day for 4–8 weeks Symptomatic pain reduction: 7–14 days; structural healing …
GHK-Cu vs BPC-157 compared: mechanisms, evidence, dosage, and when to use each. One has human clinical data, the other has broader preclinical reach.
BPC-157 vs TB-500 compared head-to-head: mechanisms, dosage, efficacy, side effects, and when to use each. Plus: the Wolverine Stack protocol.